Crystal Bioscience, SPAC 'ValueUnmiser' Listed on NASDAQ in the US
[Asia Economy Reporter Hyungsoo Park] Crystal Bioscience (CBS) announced on the 4th that it has listed a SPAC (Special Purpose Acquisition Company) called 'Valuance Merger' worth 274 billion KRW on Nasdaq, in collaboration with the US-based Valuance Capital and Credian Partners (PE). The Nasdaq ticker symbol assigned is 'VMCA'.
The new technology investment association operated by CBS participates as a limited partner (LP) in the Valuance private equity fund, investing in promising bio companies through SPACs and bio funds in the United States.
Hot Picks Today
As Samsung Falters, Chinese DRAM Surges: CXMT Returns to Profit in Just One Year
- "Most Americans Didn't Want This"... Americans Lose 60 Trillion Won to Soaring Fuel Costs
- Man in His 30s Dies After Assaulting Father and Falling from Yongin Apartment
- Samsung Union Member Sparks Controversy With Telegram Post: "Let's Push KOSPI Down to 5,000"
- "Why Make Things Like This?" Foreign Media Highlights Bizarre Phenomenon Spreading in Korea
CBS, a new technology business finance company, has been managing a venture investment association funded by the Korea Fund of Funds since June last year. Its main investment areas include bio innovative new drugs, as well as non-face-to-face sectors such as smart healthcare, information and communication technology (ICT)-based convergence innovative therapies, and bioinformatics.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
